Agilent Technologies Inc. is a global leader in the life sciences, diagnostics, and applied chemical markets, providing application-focused solutions that encompass instruments, software, services, and consumables for the entire laboratory workflow . The company operates through three main business segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab . Agilent's offerings are designed to enhance laboratory efficiency and effectiveness, catering to a wide range of scientific and industrial applications .
- Agilent CrossLab - Focuses on services, software, informatics, and consumables, designed to improve customer outcomes and is vendor neutral, serving customers regardless of their instrument choices .
- Diagnostics and Genomics - Includes cell analysis, nucleic acid solutions, and pathology solutions, with growth in nucleic acid solutions and reagent partnership businesses .
- Life Sciences and Applied Markets - Provides solutions such as liquid chromatography, mass spectrometry, gas chromatography, and spectroscopy .
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Angelica A. Reimann Executive | Senior Vice President and President, ACG | None | Angelica Reimann has been with Agilent for over 25 years and became President of the Agilent CrossLab Group in February 2024. | |
Mike Zhang Executive | Senior Vice President and President, AMG | None | Mike Zhang joined Agilent in 2002 and became President of the Applied Markets Group in August 2024. He has extensive experience in gas chromatography and mass spectrometry. | |
Padraig McDonnell Executive | President and CEO | None | Padraig McDonnell became CEO in May 2024 after serving as COO and CEO-elect. He has over 26 years of experience at Agilent and its predecessor, Hewlett-Packard Co.. | View Report → |
Robert W. McMahon Executive | Senior Vice President and CFO | Board Member at Orasure Technologies, Inc. | Robert McMahon has been CFO since September 2018. He previously held CFO roles at Hologic, Inc., and senior finance roles at Johnson & Johnson. | |
Dow R. Wilson Board | Director | Board Member at Siemens Healthineers AG | Dow Wilson has been a director since 2018. He is the former CEO of Varian Medical Systems and has extensive experience in the healthcare industry. | |
Heidi K. Kunz Board | Director | Board Member at Phathom Pharmaceuticals, Inc. | Heidi Kunz has been a director since 2000. She has extensive financial expertise and previously served as CFO for several companies. | |
Koh Boon Hwee Board | Non-Executive Chairperson of the Board | Non-Executive Chairman of Singapore Exchange Ltd.; Managing Partner at Altara Ventures Pte. Ltd.; Non-Executive Chairperson of Sunningdale Tech Ltd. | Koh Boon Hwee has been a director since 2003 and Chairperson since 2017. He brings extensive leadership and governance experience. | |
Mala Anand Board | Director | Corporate Vice President, Customer Experience at Microsoft | Mala Anand has been a director since 2019 and is also a Corporate VP at Microsoft, focusing on customer experience. | |
Otis W. Brawley Board | Director | Board Member at Incyte Corporation, Lyell Immunopharma, Inc., and PDS Biotechnology Corp | Otis Brawley has been a director since 2021. He is a Bloomberg Distinguished Professor at Johns Hopkins University and serves on multiple biotech boards. | |
Sue H. Rataj Board | Director | None | Sue Rataj has been a director since 2015. She previously served as non-Executive Chair of Cabot Corporation and held senior roles at BP. |
-
Given that the Applied Markets Group (AMG) represents $1.3 billion in annual revenue compared to the Agilent CrossLab Group (ACG) at $2.7 billion and Life Sciences and Diagnostics Group (LDG) at $2.5 billion, what are your plans to accelerate growth in AMG, and how do you plan to address potential market saturation in these applied markets?
-
You mentioned that your pathology business grew high single digits in Q4 and that genomics posted low single-digit growth after a period of declines. Given the challenging genomics market and your recent strategy pivot, how sustainable is this growth, and what are the key risks that could impact your performance in genomics moving forward?
-
With the launch of the Infinity III LC series and your expectations for increased demand starting in Q1, how confident are you in capturing market share given that competitors may have already benefited from a refresh of their installed base? What strategies do you have in place to differentiate Agilent's offerings in a potentially saturated market?
-
Regarding your guidance for fiscal year 2025, you mentioned that the "error bars" around your assumptions are wider than normal due to uncertainties such as the LC replacement cycle recovery, China stimulus, and U.S. market sentiment. Could you elaborate on the specific scenarios that could impact your guidance, and how you are preparing to mitigate potential downside risks?
-
With the acquisition of BIOVECTRA to expand your CDMO services, how do you plan to integrate this new business to drive growth, and what challenges do you anticipate in scaling up capabilities in rapidly growing therapeutic modalities like peptide synthesis and gene editing therapies? Additionally, how significant is the competitive landscape in these areas, and how will you differentiate your services?
Research analysts who have asked questions during AGILENT TECHNOLOGIES earnings calls.
Jack Meehan
Nephron Research LLC
10 questions for A
Patrick Donnelly
Citi
10 questions for A
Vijay Kumar
Evercore ISI
10 questions for A
Puneet Souda
Leerink Partners
9 questions for A
Daniel Brennan
TD Cowen
8 questions for A
Michael Ryskin
Bank of America Merrill Lynch
8 questions for A
Matthew Sykes
Goldman Sachs Group Inc.
7 questions for A
Rachel Vatnsdal Olson
JPMorgan
7 questions for A
Tycho Peterson
Jefferies
7 questions for A
Douglas Schenkel
Wolfe Research, LLC
5 questions for A
Joshua Waldman
Cleveland Research Company
5 questions for A
Daniel Leonard
Stifel Financial Corp.
4 questions for A
Brandon Couillard
Wells Fargo & Company
3 questions for A
Catherine Schulte
Baird
3 questions for A
Dan Leonard
UBS Group AG
3 questions for A
Doug Schenkel
Wolfe Research LLC
3 questions for A
Rachel Vatnsdal
JPMorgan Chase & Co.
3 questions for A
Derik De Bruin
Bank of America
2 questions for A
Paul Knight
KeyBanc Capital Markets
2 questions for A
Catherine Ramsey
BTIG
1 question for A
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
1 question for A
Elizabeth Koslosky
Goldman Sachs
1 question for A
Eve Bernstein
Bernstein Research
1 question for A
Luke Sergott
Barclays
1 question for A
S. Brandon Couillard
Wells Fargo Securities, LLC
1 question for A
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Our principal competitors in the services arena include many of our competitors from the instrument business such as: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, as well as numerous niche service providers. We compete on the basis of reliability, support quality, applications expertise, global channel coverage and price. | |
PerkinElmer Inc. | Our principal competitors in the services arena include many of our competitors from the instrument business such as: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, as well as numerous niche service providers. We compete on the basis of reliability, support quality, applications expertise, global channel coverage and price. |
Shimadzu Corporation | Our principal competitors in the services arena include many of our competitors from the instrument business such as: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, as well as numerous niche service providers. We compete on the basis of reliability, support quality, applications expertise, global channel coverage and price. |
Our principal competitors in the services arena include many of our competitors from the instrument business such as: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, as well as numerous niche service providers. We compete on the basis of reliability, support quality, applications expertise, global channel coverage and price. | |
Our principal competitors in the services arena include many of our competitors from the instrument business such as: Danaher Corporation, PerkinElmer Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc. and Waters Corporation, as well as numerous niche service providers. We compete on the basis of reliability, support quality, applications expertise, global channel coverage and price. | |
Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. | |
Affymetrix, Inc. | Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Avecia | Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. | |
Leica Biosystems, Inc. | Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. | |
Roche Ventana Medical Systems, Inc. | Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Sartorius | Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Our principal competitors in the diagnostics and genomics arena include: Abbott Laboratories, Affymetrix, Inc., a division of Thermo Fisher Scientific Inc., Avecia, a division of Nitto Denko, Illumina, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Revvity, Inc., Roche Ventana Medical Systems, Inc., a member of the Roche Group, Sartorius and Twist Bioscience Corporation. We compete on the basis of product performance, reliability, support quality, applications expertise, whole solution offering, global channel coverage and price. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
BIOVECTRA | 2024 | Agilent Technologies acquired 100% of BIOVECTRA’s stock for $915 million in cash, including the assumption of $24 million in interest‑free loans with repayment through 2040, to expand its CDMO capabilities and enhance expertise in high-growth areas like GLP‑1 and gene editing, adding significant customer relationships and projected FY2024 revenue of $140–150 million. |
Polymer Standards Service GmbH (PSS) | 2022 | Agilent acquired PSS for $41 million, contributing $19 million of goodwill and $35 million in other intangible assets, which strengthens its advanced materials and biopharma portfolio through enhanced polymer characterization expertise and support via Agilent’s instrumentation. |
Advanced Artificial Intelligence Technology | 2022 | This acquisition involved contingent consideration based on milestone payments estimated using a Monte Carlo simulation; it resulted in $21 million of recorded other intangible assets and $18 million of cash used, with an associated $150 million in amortization expense but no addition to goodwill, reflecting its strategic and financial impact. |
Recent press releases and 8-K filings for A.
- Agilent introduces Insight300M and InsightBLS next-generation liquid explosive detection systems for airport security, offering the industry’s lowest false alarm rate and rapid scan times.
- The systems are fully software-upgradable to meet evolving global LAG screening regulations, eliminating the need for costly hardware reinvestment.
- This launch represents a strategic expansion into the airport security market, building on Agilent’s 2017 acquisition of Cobalt Light Systems.
- Agilent unveiled the new Insight Series at the International Security Expo in London, providing live demonstrations to security professionals and regulators.
- Strong Q3 driven by InfinityLab LC Series and 8850 GC replacement cycles, with 10% growth in chemical and advanced materials underpinned by new product launches and services execution.
- Integration of BioVectra is on track, with completion of a production line reconfiguration in Q3 to boost 2026 capacity; NASD capacity for 2026 is fully booked, with new capacity online by late 2026/early 2027.
- The three-year Ignite transformation has delivered $80 million in span-and-layer savings and $40 million in indirect procurement cost reductions, enabling digital and innovation investments.
- China business remains stable and improving, targeting mid- to high-single-digit growth with an upcoming $140 million stimulus program opportunity.
- Margins in Q3 were pressured by higher European tariffs, variable compensation accruals, and the BioVectra shutdown, but are expected to improve by 230 bps in Q4 as these headwinds normalize.
- Q3 FY25 core 6% revenue growth, broad-based across pharma, CAM and CDMO, prompting a 25% upgrade to the full-year revenue guide.
- Tariffs in Q3 drove a 200 bp decline in gross margins; Agilent expects a 230 bp sequential margin rebound in Q4 and a net tailwind from tariff mitigations into 2026.
- Early-innings replacement cycles: InfinityLab LC systems grew mid-teens and the new 8,850 GC is targeting a 10+-year installed base, with continued growth into 2026.
- CDMO (NASD/BioVectra) posted 20% Q3 growth, with bookings well into 2026–27 and a shifting mix to ~50/50 clinical/commercial, driving long-term visibility.
- China remains a stable $300 M/qtr market, with an estimated CN¥130–150 M stimulus funnel expected to materialize in calendar Q4–Q1.
- Delivered $1.74 B in Q3 revenue (+6.1% core) and $1.37 EPS, both above guidance.
- Raised FY 2025 revenue outlook to $6.91–$6.93 B (≈4.5% core growth at midpoint), a $150 M increase from prior range.
- Q4 revenue is expected at $1.82–$1.84 B (4.8–6.0% core growth) with ~230 bps sequential operating-margin improvement.
- Ignite operating model drove double-digit cost savings, reduced management layers >15% and underpins full tariff mitigation in FY 2026.
- Strong end-market performance: Pharma +9%, Chemicals & Advanced Materials +10%, Life Sciences & Diagnostics +7%, with broad geographic growth.
- IGNITE transformation and strategic realignment: Agilent detailed its market‑based strategy, new leadership team, and transformation initiatives—including supply chain optimization and innovation investments (e.g., hiring CTO August Specht) to accelerate recurring revenue growth.
- Robust growth in key segments: The company highlighted standout performance with its PFAS business growing 70% in the quarter and NASD growing 9%, with expectations for a double‑digit pace as well as market share gains in LCMS.
- Significant capital deployment and pricing initiatives: Agilent deployed $1B in capital investments with Vectra and initiated pricing strategies that already delivered over 100 basis points in pricing improvement, alongside rapid supply chain adjustments (e.g., reducing lead times from three months to six weeks).
- International market focus amid China challenges: Despite tariff pressures, Agilent maintained a stable presence in China, leveraging previous stimulus successes and anticipating additional stimulus worth around €70M and $120M to support long‑term growth.
- Revenue of $1.67 billion and EPS of $1.31 in Q2 2025, reflecting 6% reported growth and 7% EPS growth compared to Q2 2024.
- Operating margin reached 25.1% with gross margin at 54.1%, despite incremental tariff costs impacting margins.
- The company advanced its Ignite transformation initiatives to drive efficiency, mitigate tariffs, and support strategic moves such as the BIOVECTRA acquisition, enhancing its CDMO capabilities.
- Agilent Technologies, Inc. filed an 8-K reporting its Third Amended and Restated Certificate of Incorporation, which updates key provisions of its corporate governance structure.
- The company held its Annual Meeting on March 13, 2025, where several proposals were voted on, including the election of two directors, a non-binding advisory vote on executive compensation, approval of the audit firm appointment, and a proposal to amend supermajority voting requirements.
- Agilent Technologies held its 2025 Annual Stockholders Meeting, during which the board presented key agenda items including the election of directors, an advisory vote on executive compensation for fiscal 2024, and several corporate governance proposals.
- The meeting discussed and preliminarily approved the ratification of PricewaterhouseCoopers as the independent registered public accounting firm for fiscal 2025 and the elimination of the supermajority voting requirement for certain amendments.
- A shareholder proposal for the annual election of directors was also approved, demonstrating strong support from the stockholders.
- Annual stockholders’ meeting held March 13, 2025; 285,289,591 shares outstanding as of the January 23, 2025 record date.
- Directors Oda Fraley and Michael Dolson re-elected to three-year terms, each receiving a majority of votes cast.
- Advisory vote on FY 2024 executive compensation approved with 72.47% support.
- Appointment of PricewaterhouseCoopers as independent auditor for FY 2025 ratified; amendment to eliminate the supermajority vote requirement approved with ≥80% support.
- Shareholder proposal to require annual election of all directors approved by a majority vote.
- Agilent reported a -1% Q2 instrument revenue decline, driven by conservatism in mid/large pharma capital approvals and a shutdown in emerging biotech spending, and does not expect a rebound before the end of its fiscal year on October 31.
- The Chemical & Advanced Materials (CAM) segment, representing ~21% of revenues, is guided to mid-high single-digit growth for the year, led by secular demand in lithium-ion batteries and semiconductor capacity expansions backed by government incentives.
- In its Environmental segment, Agilent estimates a $200 million PFAS testing market growing at ~15% annually, where it holds roughly 50% share and expects further expansion as U.S. EPA regulations and global testing requirements increase.
- The company is scaling its CDMO business at its Frederick NASD site—expanding from $300 million to a potential $1 billion revenue run rate—by adding Trains B, C, and D to meet rising demand for GMP-grade peptides, oligonucleotides, and CRISPR APIs.